TK PHARMA - Your health is our most valuable freight.

Exploring Hong Kong Genomic Insights: 2023 AACR-KCA Conference Highlights on Enhanced Whole Genome Sequencing

Saturday, November 18, 2023

Genome Insight, a pioneer in precision healthcare solutions advancing whole-genome technology for precise cancer and rare disease diagnosis and personalized treatment, is set to present groundbreaking real-world evidence from Hong Kong at the 2023 AACR-KCA Precision Medicine in Cancer conference in Seoul, Korea. The primary focus of Genome Insight's presentation will be on Target Enhanced Whole Genome Sequencing (TE-WGS), particularly its application in a collaborative program addressing non-small cell lung adenocarcinoma. This initiative utilized CancerVision, an exclusive TE-WGS pipeline designed specifically for solid tumors.

The presentation aims to underscore the merits of a comprehensive TE-WGS genomic assessment in comparison to conventional serial panel testing. Genome Insight will detail the case of a 78-year-old Asian man with poorly differentiated Non-Small Cell Lung Cancer (NSCLC) from Hong Kong. Despite undergoing multiple rounds of standard treatment, actionable biomarkers were identified through TE-WGS.

Key findings from the case include the detection of actionable biomarkers such as MET gene amplification (Gene Copy Number of 8), a high TMB of 14.88 muts/mb, and a whole-genome sequencing signature induced by tobacco smoking. Importantly, these biomarkers were not previously identified through traditional NGS panel testing methods.